E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
locally advanced esophageal adenocarcinoma |
lokal fortgeschrittenes Adenokarzinom des Ösophagus |
|
E.1.1.1 | Medical condition in easily understood language |
cancer of the esophagus |
lokal fortgeschrittenes Adenokarzinom der Speiseröhre |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001173 |
E.1.2 | Term | Adenocarcinoma of esophagus |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To evaluate efficacy and safety of the IMP and to evaluate biomarkers predictive for response to immune checkpoint inhibition |
|
E.2.2 | Secondary objectives of the trial |
- To determine the Best Objective Response (BOR)
- To determine PFS, DFS and OS in durvalumab vs. durvalumab + tremelimumab adjuvant treatment
- Esophageal cancer related Quality of Life (FACT-E)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
written informed consent
- Histologically confirmed, resectable adenocarcinoma of the esophagus (uT2, uN+, cM0 or uT3, cNx, cM0)
- No preceding cytotoxic or targeted therapy
- No prior partial or complete tumour resection
- Male or female patients ≥ 18 years of age at time of study entry
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- Study participants must be willing to undergo at least 2 biopsies (baseline, after neoadjuvant treatment)
- Life expectancy of ≥ 12 months
- Body weight > 30kg |
|
E.4 | Principal exclusion criteria |
- Study participants with squamous cell carcinoma of the oesophagus
- Prior treatment with chemotherapy, targeted therapy or radiotherapy for treatment of advanced disease
- Patients are excluded if they are not resectable because of tumor infiltrating any other organs (cM1), except the stomach, with risk for R1 or R2 resection or if they are not resectable in case of other serious or uncontrolled medical disease.
- Patients with tumour stadium less than uT3 or confirmed metastatic diseases
- Any other serious or uncontrolled medical disorder, active infections, physical exam findings, laboratory finding, altered mental status, or psychiatric condition that, in the opinion of the investigator, would limit a study participant’s ability to comply with the study requirements, substantially increase risk to the study participant, or impact the interpretability or study results
- Presence or history of any other primary malignancy other than adenocarcinoma of the esophagus within 5 years prior to enrolment into the trial, except for adequately treated basal or squamous cell carcinoma of the skin or any adequately treated in situ carcinoma
- Pregnant or breastfeeding females
- Patients has known current symptomatic congestive heart failure (NYHA III and IV), unstable angina pectoris, or cardiac arrhythmia |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To assess the rate of complete pathological response. When durvalumab is added to CROSS (carboplatin/paclitaxel + 41,4Gy RTx) in the neoadjuvant setting and PFS in the adjuvant therapy/maintenance with durvalumab after surgery.
The primary endpoint for safety is incidence, severity and grading of treatment emergent AEs and SAEs
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. Response to neoadjuvant treatment (CR, PR, SD, PD) as defined by RECIST 1.1. and iRECIST criteria
2. PFS and OS in durvalumab vs. durvalumab+tremelimumab adjuvant treatment
3. Oesophageal cancer related Quality of Life (FACT-E) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Weeks 10 to 11, that means one to three weeks before surgery
2. Until disease progression (PFS) and/or until 12 months after last administering IMP
3. From screening until visit 20 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LPLV (last patient last visit) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |